TriSalus Life Sciences (NASDAQ:TLSI) reported slightly lower first-quarter revenue and reduced its full-year 2026 revenue outlook, citing disruption from a broad commercial reorganization and a delayed FDA review for its next-generation TriNav Advance device.
President and Chief Executive Officer M
OptimizeRx (NASDAQ:OPRX) reported first-quarter fiscal 2026 results that topped consensus expectations, while management lowered its full-year revenue outlook, citing continued caution among life sciences customers and shorter contract commitments tied in part to most-favored-nation pricing dynamics
Paysign (NASDAQ:PAYS) reported what executives described as the strongest start to a year in the company’s history, with first-quarter 2026 revenue rising 50.8% year over year to $28 million and profitability expanding sharply as its patient affordability business became its largest revenue contribu
QuickLogic (NASDAQ:QUIK) reported higher first-quarter fiscal 2026 revenue and reiterated expectations for strong full-year growth, as management highlighted progress in radiation-hardened FPGA products, embedded FPGA intellectual property and chiplet-related opportunities.
President and Chief Exec
Relmada Therapeutics (NASDAQ:RLMD) said it remains on track to begin its Phase 3 RESCUE registrational program for NDV-01 in mid-2026 after reporting 12-month Phase 2 data in non-muscle invasive bladder cancer and strengthening its balance sheet through a private financing.
On the company’s first-q
Looking for a growth ETF for your next $1,000 investment? XIT offers long‑term performance and concentrated exposure to Canada’s top technology stocks.
NeuroPace (NASDAQ:NPCE) raised its 2026 revenue outlook after reporting first-quarter results that management said reflected continued demand for its RNS System and improving commercial execution across epilepsy treatment centers.
The company reported total revenue of $22.1 million for the first qu
Nextpower (NASDAQ:NXT) reported a strong finish to fiscal 2026, with executives pointing to record backlog, growth in its core solar tracker business and a broader push into power plant technology as key themes for the year ahead.
Chief Executive Officer and Founder Dan Shugar said the company deli
Nyxoah (NASDAQ:NYXH) reported 13% sequential worldwide net revenue growth in the first quarter of 2026, driven primarily by continued adoption of its Genio system in the United States, where the company is in its second full quarter of commercialization.
Chief Executive Officer Olivier Taelman said
Spectral AI (NASDAQ:MDAI) said it remains on track toward potential U.S. regulatory clearance and commercialization of its DeepView system for burn assessment, while reporting lower first-quarter research and development revenue tied to the completion of work under a federal contract.
On the compan
MaxCyte (NASDAQ:MXCT) reported lower first-quarter revenue compared with the prior year, as management said discontinued SPL programs and inventory management by its largest customer weighed on core revenue, while milestone revenue from a registrational-stage program helped offset part of the declin
National CineMedia (NASDAQ:NCMI) reported first-quarter 2026 results that management said were in line with expectations, as the cinema advertising company faced typical seasonal weakness, advertising competition from the Winter Olympics and a one-week fiscal calendar shift.
Chief Executive Officer
Kura Oncology (NASDAQ:KURA) reported $5.8 million in first-quarter net product revenue from KOMZIFTI, its first commercial product, and said the launch is showing early signs of physician uptake, broad payer coverage and use in combination regimens, according to management’s earnings call for the fi
Lumexa Imaging (NASDAQ:LMRI) reported first-quarter results that management said were in line with expectations, as growth in advanced imaging modalities helped offset seasonal volume pressure and weather-related disruptions.
Chief Executive Officer Caitlin Zulla said the company “recovered our mom
